常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-14.79/-1.82
|
|
企业价值
149.91M
|
| 资产负债 |
|
每股账面净值
-11.91
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
40.50M
|
|
每股收益
8.17
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/11/19 12:33 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADCplatforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175. |

27.705 
